June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
One-year Outcome in a Randomized Clinical Trial of Treatment for Symptomatic Convergence Insufficiency in Children (CITT-ART)
Author Affiliations & Notes
  • Marjean T Kulp
    The Ohio State University, Columbus, Ohio, United States
  • Ann Morrison
    The Ohio State University, Columbus, Ohio, United States
  • G.Lynn Mitchell
    The Ohio State University, Columbus, Ohio, United States
  • Mitchell Scheiman
    Salus University, Elkins Park, Pennsylvania, United States
  • Susan A Cotter
    Marshall B Ketchum University, Fullerton, California, United States
  • Erin Jenewein
    Salus University, Elkins Park, Pennsylvania, United States
  • Eric Borsting
    Marshall B Ketchum University, Fullerton, California, United States
  • Richard W Hertle
    Akron Children's Hospital, Akron, Ohio, United States
  • Annette Bade
    Nova Southeastern University, Fort Lauderdale, Florida, United States
  • Footnotes
    Commercial Relationships   Marjean Kulp None; Ann Morrison None; G.Lynn Mitchell None; Mitchell Scheiman None; Susan Cotter None; Erin Jenewein None; Eric Borsting None; Richard Hertle None; Annette Bade None
  • Footnotes
    Support  Supported by the National Eye Institute of the National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 5U10EY022599, 5U10EY0226, 5U10EY022595, 5U10 EY022592, 5U10 EY022586, 5U10EY022600, 5U10EY022587, 5U10EY022596, 5U10EY022594
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1459. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marjean T Kulp, Ann Morrison, G.Lynn Mitchell, Mitchell Scheiman, Susan A Cotter, Erin Jenewein, Eric Borsting, Richard W Hertle, Annette Bade; One-year Outcome in a Randomized Clinical Trial of Treatment for Symptomatic Convergence Insufficiency in Children (CITT-ART). Invest. Ophthalmol. Vis. Sci. 2023;64(8):1459.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the long-term stability of clinical measures of convergence (near point of convergence [NPC] and positive fusional vergence [PFV]) in 9- to 14-year-old children enrolled in the Convergence Insufficiency Treatment Trial-Attention & Reading Trial (CITT-ART).

Methods : 310 children ages 9 to 14 years with symptomatic CI were randomized in a 2:1 ratio to 16 weeks of office-based vergence/accommodative therapy or placebo therapy, respectively. At the 16-week primary outcome, children who were asymptomatic were assigned maintenance therapy and those who were symptomatic were offered treatment. NPC and PFV were measured 1 year after completion of the 16-week visit. We compared findings and the percentages of children with normal (<6cm) and/or improved NPC (≥4cm) and normal (passing Sheard’s criterion and base-out break >15pd) and/or improved PFV (≥10pd) at 16 weeks and 1 year.

Results : Of participants who completed the 16-week outcome, 88.8% returned at 1 year (90% assigned to vergence/accommodative therapy; 86% assigned to placebo therapy). For participants in the vergence/accommodative therapy group who did not report any additional therapy after 16 weeks, mean adjusted NPC did not significantly change (-0.37cm; 95% CI: -0.97 to 0.23cm) and mean adjusted PFV decreased slightly between 16 weeks to 1 year, but this change was not clinically relevant (-4.80pd; 95% CI: -6.50 to -3.10pd). Thus, NPC and PFV remained clinically normal at 1 year (4.37cm ± 3.2cm and 29.38pd ± 10.4pd, respectively) for vergence/accommodative therapy group participants and there was no significant change in the percentages classified as either “normal and improved” or “normal and/or improved” based on NPC and PFV (P>.086) at year 1 compared to the 16-week outcome. There were no significant changes in the clinical measures of placebo group participants who did not report any additional therapy between the 16-week outcome and 1 year (NPC: 1.03cm, 95% CI: -0.31 to 2.37cm; PFV: 0.54pd, 95% CI:-1.98pd to 3.06pd)(P-values > 0.10).

Conclusions : Children ages 9 to 14 years old maintained their improvements in clinical measures of convergence after 16 weeks of office-based vergence/accommodative therapy for symptomatic convergence insufficiency. Mean NPC and PFV values at 1 year remained clinically normal.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×